Literature DB >> 8745007

A new improved sub-unit vaccine for plague: the basis of protection.

E D Williamson1, S M Eley, K F Griffin, M Green, P Russell, S E Leary, P C Oyston, T Easterbrook, K M Reddin, A Robinson.   

Abstract

In this study, we have determined the limit of protection achievable by immunisation with sub-units of Yersinia pestis against the development of plague in an experimental animal model. Co-immunisation with the purified culture-derived F1 and the recombinant V sub-units afforded a greater level of protection than with either sub-unit alone. The protection given by the combined sub-units was several orders of magnitude greater than that afforded by the whole cell killed (Cutter USP) vaccine and was equivalent to that achieved by vaccination with EV76, the live attenuated Y. pestis vaccine strain. However, the combined sub-unit vaccine has clear advantages over the live vaccine in terms of safety of use and absence of side-effects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8745007     DOI: 10.1111/j.1574-695X.1995.tb00196.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  78 in total

1.  Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis.

Authors:  Jim Hill; Catherine Copse; Sophie Leary; Anthony J Stagg; E Diane Williamson; Richard W Titball
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

2.  Protein microarray for profiling antibody responses to Yersinia pestis live vaccine.

Authors:  Bei Li; Lingxiao Jiang; Qifeng Song; Junxin Yang; Zeliang Chen; Zhaobiao Guo; Dongsheng Zhou; Zongmin Du; Yajun Song; Jin Wang; Hongxia Wang; Shouyi Yu; Jian Wang; Ruifu Yang
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

3.  Development of a vaccinia virus based reservoir-targeted vaccine against Yersinia pestis.

Authors:  Debaditya Bhattacharya; Joan Mecsas; Linden T Hu
Journal:  Vaccine       Date:  2010-09-25       Impact factor: 3.641

4.  Evaluation of combinatorial vaccines against anthrax and plague in a murine model.

Authors:  Amanda B DuBois; Lucy C Freytag; John D Clements
Journal:  Vaccine       Date:  2007-04-20       Impact factor: 3.641

Review 5.  Interaction between Yersinia pestis and the host immune system.

Authors:  Bei Li; Ruifu Yang
Journal:  Infect Immun       Date:  2008-02-04       Impact factor: 3.441

6.  A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague.

Authors:  Hitoki Yamanaka; Teri Hoyt; Xinghong Yang; Sarah Golden; Catharine M Bosio; Kathryn Crist; Todd Becker; Massimo Maddaloni; David W Pascual
Journal:  Infect Immun       Date:  2008-08-11       Impact factor: 3.441

7.  Modified caspase-3 assay indicates correlation of caspase-3 activity with immunity of nonhuman primates to Yersinia pestis infection.

Authors:  Susan Welkos; Sarah Norris; Jeffrey Adamovicz
Journal:  Clin Vaccine Immunol       Date:  2008-05-14

8.  Comparison of virulence between the Yersinia pestis Microtus 201, an avirulent strain to humans, and the vaccine strain EV in rhesus macaques, Macaca mulatta.

Authors:  Guang Tian; Zhizhen Qi; Yefeng Qiu; Xiaohong Wu; Qingwen Zhang; Xiaoyan Yang; Youquan Xin; Jian He; Yujing Bi; Qiong Wang; Jiyuan Zhou; Yanxiao Fan; Yazhou Zhou; Yongqiang Jiang; Ruifu Yang; Xiaoyi Wang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

9.  An IL-12 DNA vaccine co-expressing Yersinia pestis antigens protects against pneumonic plague.

Authors:  Hitoki Yamanaka; Teri Hoyt; Richard Bowen; Xinghong Yang; Kathryn Crist; Sarah Golden; Massimo Maddaloni; David W Pascual
Journal:  Vaccine       Date:  2008-10-26       Impact factor: 3.641

10.  Different pathologies but equal levels of responsiveness to the recombinant F1 and V antigen vaccine and ciprofloxacin in a murine model of plague caused by small- and large-particle aerosols.

Authors:  Richard J Thomas; Daniel Webber; Aaron Collinge; Anthony J Stagg; Stephen C Bailey; Alejandro Nunez; Amanda Gates; Pramukh N Jayasekera; Rosa R Taylor; Steve Eley; Richard W Titball
Journal:  Infect Immun       Date:  2009-02-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.